ArticlePloS one2025
Evaluation of caffeine modulation of topiramate effect on locomotor activity of zebrafish larvae in pentylenetetrazol-induced seizure model.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Caffeine Biotransformation in Zebrafish Larvae: Integrated LC-MS/MS Quantification and FTIR Spatial Mapping.Molecules (Basel, Switzerland) · 2026Article
- Unveiling the influence of caffeine on topiramate: metabolomic marker analysis using liquid chromatography-mass spectrometry.Frontiers in molecular biosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a prevalent neurological condition marked by seizures that lead to neurobiological and behavioral impairments. Caffeine (CAF), the world's most consumed stimulant, reportedly affects both epileptic seizures and the efficacy of antiepileptic drugs, particularly topiramate (TPM). This study aimed to investigate the effects of CAF on TPM in a pentylenetetrazol (PTZ)-induced seizure model using zebrafish larvae. Four days post-fertilization Danio rerio larvae were incubated for 18 hours with CAF, TPM, or CAF+TPM, followed by an assessment of locomotor activity. Seizures were induced by adding PTZ to achieve a final concentration of 20 mM. In the PTZ-induced seizure model, the application of CAF in doses over 50 mg/L resulted in a decrease in the average movement. TPM ( > 50 μM) significantly protected larvae against the PTZ. The addition of 15 mg/L CAF to TPM did not affect larval activity at any TPM concentration tested; however, higher doses of CAF significantly reduced larval activity. CAF doses above 25 mg/L altered the activity of larvae treated with TPM in the PTZ-induced seizure model. Larvae exhibited differential heart rate (HR) responses to CAF exposure across doses. CAF at 75 mg/L significantly increased HR, while doses of 175 mg/L and higher induced bradycardia. TPM, across all tested doses, did not independently influence HR. The study provides valuable insights into the interactions between CAF and TPM, which may inform future research on human epilepsy. However, the extrapolation of these results to other species should be approached cautiously due to physiological differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.